Institut National De La Sante Et De La Recherche Medicale

Institut Pasteur

Other

Roche Molecular Systems, Inc.

Institute Pasteur

Institut Nationale De La Sante

Sylvie Beaudenon

Gerard Orth

Dina Kremsdorf

Odile Croissant

Michel Favre

Gerard Pehau-Arnaudet

Michele Longuet

A purified human papillomavirus gene selected from the group consisting of E1, E6-E7, L1, and L2, wherein said human papillomavirus is selected from the group consisting of HPV-2d, HPV-10b, HPV-14a, HPV-14b, HPV-15, HPV-17a, HPV-17b, HPV-19, HPV-20, HPV-21, HPV-22, HPV-23, HPV-24, HPV-28, HPV-29, HPV-31, HPV-32, HPV-IP2 and HPV-IP4. Polypeptides encoded by these genes. The polypeptides can be used in immunogenic compositions.

Immunogenic compositions of human papillomavirus and sera produced therefrom

The invention concerns human papillomavirus (HPV) DNA and more particularly the probes derived from these papillomaviruses, as well as the methods of detecting HPV using these probes. These human papillomaviruses are designated as HPV-2d, HPV-10b, HPV-14a, HPV-14b, HPV-15, HPV-17a, HPV-17b, HPV-19, HPV-20, HPV-21, HPV-22, HPV-23, HPV-24, HPV-28, HPV-29, HPV-31, HPV-32, HPV-IP2 and HPV-IP4.

Immunogenic compositions of human papillomavirus

The genomes of two novel human papillomavirus (HPV) types, HPV68 and HPV70, were cloned from a low grade cervical intraepithelial neoplasia and a vulvar papilloma, respectively, and sequenced. Both types are related to HPV39, a potentially oncogenic virus. HPV68 and HPV70 were also detected in genital intraepithelial neoplasia from three patients and one patient, respectively. Comparison with sequence data in the literature indicates that the subgenomic ME180-HPV DNA fragment, cloned from a carcinoma cell line, corresponds to an HPV68 subtype and that several HPV DNA fragments amplified by PCR from genital neoplasia represent worldwide distributed variants of HPV68 and HPV70.

Genital human papillomavirus type 68a (HPV-68a), related to the

The invention relates to papillomaviruses, particularly to DNA-HPVs isolated from the papillomaviruses IP5 and IP6, the restriction maps of papillomaviruses IP5 and IP6, and also to probes containing these DNA-HPVs or fragments obtained from them. The invention relates, in addition, to 'kits' containing distinct groups of probes, containing one of these DNA-HPVs or DNA-HPV fragments, as well as a procedure for the detection and identification of papillomaviruses which makes use of these different probes.

Probes for papillomaviruses and an in vitro diagnostic procedure for

Papillomavirus probe and a process for in vitro diagnosis of

The invention relates to human papillomaviruses HPV, particularly to HPV-DNAs isolated from papillomaviruses HPV-2d, HPV-10b, HPV-14a, HPV-14b, HPV-15, HPV-17a, HPV-17b, HPV-19, HPV-20, HPV-21, HPV-22, HPV-23, HPV-24, HPV-28, HPV-29, HPV-31, HPV-32, HPV-IP2 and HPV-IP4. The invention also relates to DNA capable of hybridizing with the HPV-DNAs or fragments thereof, to kits containing distinct groups of probes containing one or more of these HPV-DNAs or fragments thereof, and to procedures for detecting and identifying HPV in tissue.

Papillomavirus probe and process for in vitro diagnosis of

The invention relates to papillomaviruses, particularly to DNA-HPVs isolated from the papillomaviruses IP5 and IP6, the restriction maps of which are presented in FIGS. 10 and 11, and also to probes containing these DNA-HPVs or fragments obtained from them. The invention relates, in addition, to 'kits' containing distinct groups of probes, containing one of these DNA-HPVs or DNA-HPV fragments, as well as a procedure for the detection and identification of papillomaviruses which makes use of these different probes.

Growing community of inventors

Esbly, France

Sylvie Beaudenon